Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://medibazar.eu
Are you over 18 and want to see adult content?
A complete backup of https://dia-burs.ru
Are you over 18 and want to see adult content?
A complete backup of https://belga.be
Are you over 18 and want to see adult content?
A complete backup of https://xtremelysocial.com
Are you over 18 and want to see adult content?
A complete backup of https://nuxe.com
Are you over 18 and want to see adult content?
A complete backup of https://skupka59.ru
Are you over 18 and want to see adult content?
A complete backup of https://middletownri.com
Are you over 18 and want to see adult content?
A complete backup of https://naminc.org
Are you over 18 and want to see adult content?
A complete backup of https://woopra.com
Are you over 18 and want to see adult content?
A complete backup of https://muller-designs.com
Are you over 18 and want to see adult content?
A complete backup of https://richmondfolkfestival.org
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of watchreviewblog.com
Are you over 18 and want to see adult content?
A complete backup of sanonz.github.io
Are you over 18 and want to see adult content?
A complete backup of vr-banknordeifel.de
Are you over 18 and want to see adult content?
A complete backup of jaytexconstruction.com.au
Are you over 18 and want to see adult content?
A complete backup of deepsouthtour.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of thefitnessman.myshopify.com
Are you over 18 and want to see adult content?
Text
field.
NEWS - KHK4083
Kyowa Kirin to get $400 million upfront in KHK4083 licensing deal. 02-06-2021. Shares of Japanese drugmaker Kyowa Kirin (TYO: 4151) were up 8% at 3,560 yen on news of a lucrative licensing MORPHOSYS HOCKS ROYALTIES TO BUY CONSTELLATION PHARMA Royalty Pharma. MorphoSys. Shares of US cancer drug maker Constellation Pharmaceuticals closed up a massive 66.7% at $33.74 yesterday. To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the POSITIVE PIVOTAL PHASE III DATA FOR ROCHE’S TECENTRIQ To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.. Or, if you're only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcingBIOSIMILARS NEWS
15-05-2021. Recently-formed Viatris, the combination of Mylan with Pfizer’s Upjohn business, has reported results. Article. Progress on proposed biosimilars of eye drugs Eylea and Lucentis. 04-05-2021. Article. Boehringer says data supports interchangeability of Cyltezo with Humira. 24-04-2021. Article. BRIEF—ASTRAZENECA ANNOUNCES DEATH OF JOSÉ BASELGA, HEAD OF BRIEF—AstraZeneca announces death of José Baselga, head of oncology R&D. UK pharma major AstraZeneca yesterday announced the death of José Baselga, executive vice president oncology R&D, and member of its senior executive team. Pascal Soriot, chief executive of AstraZeneca, commented: “An outstanding scientific leader, Joséleaves a
NEWS - CAPSIGEN
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
THE FUTURE OF BIOLOGICSSEE MORE ON THEPHARMALETTER.COM JAPAN PHARMA MARKET REVIEW Japan pharma market review. Gross domestic product (GDP) in Japan is about $5 trillion, and the country’s pharmaceutical market is one of the largest in the world, with figures from the Ministry of Health, Labour and Welfare (MHLW) indicating a market value of about $95 billion, including non-prescription medications.KINEDAK LAUNCH
Kinedak launch. 31-05-1992. Comments (0) Print. - Kinedak (epalrestat) has recently been launched in Japan by Ono Pharmaceutical. Ono expects the drug. To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from thesharpest
AUTHORITATIVE PHARMA AND BIOTECH NEWS The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
NEWS - KHK4083
Kyowa Kirin to get $400 million upfront in KHK4083 licensing deal. 02-06-2021. Shares of Japanese drugmaker Kyowa Kirin (TYO: 4151) were up 8% at 3,560 yen on news of a lucrative licensing MORPHOSYS HOCKS ROYALTIES TO BUY CONSTELLATION PHARMA Royalty Pharma. MorphoSys. Shares of US cancer drug maker Constellation Pharmaceuticals closed up a massive 66.7% at $33.74 yesterday. To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the POSITIVE PIVOTAL PHASE III DATA FOR ROCHE’S TECENTRIQ To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.. Or, if you're only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcingBIOSIMILARS NEWS
15-05-2021. Recently-formed Viatris, the combination of Mylan with Pfizer’s Upjohn business, has reported results. Article. Progress on proposed biosimilars of eye drugs Eylea and Lucentis. 04-05-2021. Article. Boehringer says data supports interchangeability of Cyltezo with Humira. 24-04-2021. Article. BRIEF—ASTRAZENECA ANNOUNCES DEATH OF JOSÉ BASELGA, HEAD OF BRIEF—AstraZeneca announces death of José Baselga, head of oncology R&D. UK pharma major AstraZeneca yesterday announced the death of José Baselga, executive vice president oncology R&D, and member of its senior executive team. Pascal Soriot, chief executive of AstraZeneca, commented: “An outstanding scientific leader, Joséleaves a
NEWS - CAPSIGEN
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
THE FUTURE OF BIOLOGICSSEE MORE ON THEPHARMALETTER.COM JAPAN PHARMA MARKET REVIEW Japan pharma market review. Gross domestic product (GDP) in Japan is about $5 trillion, and the country’s pharmaceutical market is one of the largest in the world, with figures from the Ministry of Health, Labour and Welfare (MHLW) indicating a market value of about $95 billion, including non-prescription medications.KINEDAK LAUNCH
Kinedak launch. 31-05-1992. Comments (0) Print. - Kinedak (epalrestat) has recently been launched in Japan by Ono Pharmaceutical. Ono expects the drug. To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from thesharpest
LOGIN - THE PHARMA LETTER The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
BRIEF—FULL ANAKINRA COVID-19 PNEUMONIA RESULTS SET UP BRIEF—Full anakinra COVID-19 pneumonia results set up regulator talks. Full results have been presented from the investigator-sponsored SAVE-MORE study of anakinra in COVID-19 pneumonia by Swedish Orphan Biovitrum, the company more commonly-known as Sobi, and the Hellenic Institute for the Study of Sepsis. Day 28 results show early treatment BRIEF—CHINA BUYS 100 MILLION DOSES OF BIONTECH/PFIZER VACCINE BioNTech. BioNTech and Shanghai Fosun Pharmaceutical have agreed to supply China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against COVID-19. Approved in several countries including the UK, USA and Canada, the deal with China is subject to the product’s approval from the country’s medicinesregulator.
NEWS - BYONDIS
1 day ago · The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field.GENERICS NEWS
Viatris’ 2021 financial guidance misses expectations. Viatris, the newly-formed generics power-house resulting from the merger of Mylan and Pfizer’s Upjohn unit, saw its share fall more than 11% to $16.30 pre-market today, after it announced 2021 financial guidance. See allGenerics news.
BRIEF—METYRAPONE EFFECTIVE AND SAFE IN ENDOGENOUS CUSHING HRA Pharma Rare Diseases, an affiliate of privately-held French healthcare company HRA Pharma, has revealed data from the six-month extension of PROMPT, the first ever prospective study designed to evaluate metyrapone long-term efficacy and tolerability in NEWS - MOLNUPIRAVIR - THE PHARMA LETTER The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
NEWS - WEGOVY
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
NEWS - BIONTECH, VACCINES, GLOBAL - THEPHARMALETTER.COM The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
PHARMACEUTICAL
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
AUTHORITATIVE PHARMA AND BIOTECH NEWS The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
GOVERNMENT AFFAIRS
BRIEF—India’s SII to extend freeze on exports of COVID-19 jabs. 19-05-2021. The world’s biggest vaccine maker, the Serum Institute of India (SII), plans to extend its halt on. Coronavirus Focus On Government Affairs India Infectious diseases Pharmaceutical Production Serum Institute of India Vaccines. InBrief.RARE DISEASES
Sarepta leaps on mainly positive SRP-5051 results in patients with DMD. 04-05-2021. Shares of Sarepta Therapeutics closed up nearly 9% at $77.11 yesterday, after the US rare diseases specialist. Biotechnology Drug Trial Duchenne Muscular dystrophy Musculoskeletal One to Watch Companies Rare diseases Research Sarepta Therapeutics SRP-5051 USA. BRIEF—CHINA BUYS 100 MILLION DOSES OF BIONTECH/PFIZER VACCINE BioNTech. BioNTech and Shanghai Fosun Pharmaceutical have agreed to supply China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against COVID-19. Approved in several countries including the UK, USA and Canada, the deal with China is subject to the product’s approval from the country’s medicinesregulator.
GENERICS NEWS
Viatris’ 2021 financial guidance misses expectations. Viatris, the newly-formed generics power-house resulting from the merger of Mylan and Pfizer’s Upjohn unit, saw its share fall more than 11% to $16.30 pre-market today, after it announced 2021 financial guidance. See allGenerics news.
BRIEF—ASTRAZENECA ANNOUNCES DEATH OF JOSÉ BASELGA, HEAD OF BRIEF—AstraZeneca announces death of José Baselga, head of oncology R&D. UK pharma major AstraZeneca yesterday announced the death of José Baselga, executive vice president oncology R&D, and member of its senior executive team. Pascal Soriot, chief executive of AstraZeneca, commented: “An outstanding scientific leader, Joséleaves a
IS PHARMA UNDERINVESTING IN MENTAL HEALTH? The global pharmaceutical industry has spent well over a trillion dollars on research and development in the last ten years, and analysts expect annual investment levels to grow by around 3% annually, reaching up to $200 billion per year by 2022. Far and away the largest market for pharma investment is the USA, which now spendsalmost 60 cents
THE FUTURE OF BIOLOGICSSEE MORE ON THEPHARMALETTER.COM JAPAN PHARMA MARKET REVIEWMEXICO PHARMACEUTICAL MARKETPHARMACEUTICAL MARKET SIZEUS PHARMACEUTICAL MARKET Japan pharma market review. Gross domestic product (GDP) in Japan is about $5 trillion, and the country’s pharmaceutical market is one of the largest in the world, with figures from the Ministry of Health, Labour and Welfare (MHLW) indicating a market value of about $95 billion, including non-prescription medications. NOVO NORDISK TO EXPAND INSULIN CAPACITY IN RUSSIA 06-11-2020. Article Sanofi plans four-fold increase in insulin production in Russia. 31-10-2017. Article Novo Nordisk invests $60 million in expansion of Kalundborg site. 04-07-2016. Article Novo Nordisk plans to meet entire Russian demand for insulin over the next few years. 02-05-2016. AUTHORITATIVE PHARMA AND BIOTECH NEWS The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
GOVERNMENT AFFAIRS
BRIEF—India’s SII to extend freeze on exports of COVID-19 jabs. 19-05-2021. The world’s biggest vaccine maker, the Serum Institute of India (SII), plans to extend its halt on. Coronavirus Focus On Government Affairs India Infectious diseases Pharmaceutical Production Serum Institute of India Vaccines. InBrief.RARE DISEASES
Sarepta leaps on mainly positive SRP-5051 results in patients with DMD. 04-05-2021. Shares of Sarepta Therapeutics closed up nearly 9% at $77.11 yesterday, after the US rare diseases specialist. Biotechnology Drug Trial Duchenne Muscular dystrophy Musculoskeletal One to Watch Companies Rare diseases Research Sarepta Therapeutics SRP-5051 USA. BRIEF—CHINA BUYS 100 MILLION DOSES OF BIONTECH/PFIZER VACCINE BioNTech. BioNTech and Shanghai Fosun Pharmaceutical have agreed to supply China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against COVID-19. Approved in several countries including the UK, USA and Canada, the deal with China is subject to the product’s approval from the country’s medicinesregulator.
GENERICS NEWS
Viatris’ 2021 financial guidance misses expectations. Viatris, the newly-formed generics power-house resulting from the merger of Mylan and Pfizer’s Upjohn unit, saw its share fall more than 11% to $16.30 pre-market today, after it announced 2021 financial guidance. See allGenerics news.
BRIEF—ASTRAZENECA ANNOUNCES DEATH OF JOSÉ BASELGA, HEAD OF BRIEF—AstraZeneca announces death of José Baselga, head of oncology R&D. UK pharma major AstraZeneca yesterday announced the death of José Baselga, executive vice president oncology R&D, and member of its senior executive team. Pascal Soriot, chief executive of AstraZeneca, commented: “An outstanding scientific leader, Joséleaves a
IS PHARMA UNDERINVESTING IN MENTAL HEALTH? The global pharmaceutical industry has spent well over a trillion dollars on research and development in the last ten years, and analysts expect annual investment levels to grow by around 3% annually, reaching up to $200 billion per year by 2022. Far and away the largest market for pharma investment is the USA, which now spendsalmost 60 cents
THE FUTURE OF BIOLOGICSSEE MORE ON THEPHARMALETTER.COM JAPAN PHARMA MARKET REVIEWMEXICO PHARMACEUTICAL MARKETPHARMACEUTICAL MARKET SIZEUS PHARMACEUTICAL MARKET Japan pharma market review. Gross domestic product (GDP) in Japan is about $5 trillion, and the country’s pharmaceutical market is one of the largest in the world, with figures from the Ministry of Health, Labour and Welfare (MHLW) indicating a market value of about $95 billion, including non-prescription medications. NOVO NORDISK TO EXPAND INSULIN CAPACITY IN RUSSIA 06-11-2020. Article Sanofi plans four-fold increase in insulin production in Russia. 31-10-2017. Article Novo Nordisk invests $60 million in expansion of Kalundborg site. 04-07-2016. Article Novo Nordisk plans to meet entire Russian demand for insulin over the next few years. 02-05-2016.NEWS - ATC
7 hours ago · The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field. LOGIN - THE PHARMA LETTER The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
PHARMACEUTICAL NEWS
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
NEWS - AEF0117
2 hours ago · The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field. MERGERS & ACQUISITIONS Roivant merging with Montes Archimedes to go public in $7.3 billion SPAC deal. 04-05-2021. Switzerland-based biopharma Roivant Sciences and Montes Archimedes Acquisition, a special purpose acquisition. Biotechnology Companies, mergers and acquisitions Management Montes Archimedes Acquisition Roivant Sciences Switzerland USA. BRIEF—CHINA BUYS 100 MILLION DOSES OF BIONTECH/PFIZER VACCINE BioNTech. BioNTech and Shanghai Fosun Pharmaceutical have agreed to supply China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against COVID-19. Approved in several countries including the UK, USA and Canada, the deal with China is subject to the product’s approval from the country’s medicinesregulator.
BRIEF—METYRAPONE EFFECTIVE AND SAFE IN ENDOGENOUS CUSHING HRA Pharma Rare Diseases, an affiliate of privately-held French healthcare company HRA Pharma, has revealed data from the six-month extension of PROMPT, the first ever prospective study designed to evaluate metyrapone long-term efficacy and tolerability inNEWS - KHK4083
Kyowa Kirin to get $400 million upfront in KHK4083 licensing deal. 02-06-2021. Shares of Japanese drugmaker Kyowa Kirin (TYO: 4151) were up 8% at 3,560 yen on news of a lucrative licensing. NEWS - MOSUNETUZUMAB The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
BRIEF—ICR ANNOUNCES APPOINTMENT OF NEW CEO BRIEF—ICR announces appointment of new CEO. Professor Kristian Helin, a world-leading cancer researcher with exceptional leadership experience in three different countries, will become chief executive of the UK’s Institute of Cancer Research, in September. Prof Helin is a pioneer in understanding how changes to the way the DNA code isread
AUTHORITATIVE PHARMA AND BIOTECH NEWS The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
GOVERNMENT AFFAIRS
BRIEF—India’s SII to extend freeze on exports of COVID-19 jabs. 19-05-2021. The world’s biggest vaccine maker, the Serum Institute of India (SII), plans to extend its halt on. Coronavirus Focus On Government Affairs India Infectious diseases Pharmaceutical Production Serum Institute of India Vaccines. InBrief.RARE DISEASES
Sarepta leaps on mainly positive SRP-5051 results in patients with DMD. 04-05-2021. Shares of Sarepta Therapeutics closed up nearly 9% at $77.11 yesterday, after the US rare diseases specialist. Biotechnology Drug Trial Duchenne Muscular dystrophy Musculoskeletal One to Watch Companies Rare diseases Research Sarepta Therapeutics SRP-5051 USA. BRIEF—CHINA BUYS 100 MILLION DOSES OF BIONTECH/PFIZER VACCINE BioNTech. BioNTech and Shanghai Fosun Pharmaceutical have agreed to supply China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against COVID-19. Approved in several countries including the UK, USA and Canada, the deal with China is subject to the product’s approval from the country’s medicinesregulator.
GENERICS NEWS
Viatris’ 2021 financial guidance misses expectations. Viatris, the newly-formed generics power-house resulting from the merger of Mylan and Pfizer’s Upjohn unit, saw its share fall more than 11% to $16.30 pre-market today, after it announced 2021 financial guidance. See allGenerics news.
BRIEF—ASTRAZENECA ANNOUNCES DEATH OF JOSÉ BASELGA, HEAD OF BRIEF—AstraZeneca announces death of José Baselga, head of oncology R&D. UK pharma major AstraZeneca yesterday announced the death of José Baselga, executive vice president oncology R&D, and member of its senior executive team. Pascal Soriot, chief executive of AstraZeneca, commented: “An outstanding scientific leader, Joséleaves a
IS PHARMA UNDERINVESTING IN MENTAL HEALTH? The global pharmaceutical industry has spent well over a trillion dollars on research and development in the last ten years, and analysts expect annual investment levels to grow by around 3% annually, reaching up to $200 billion per year by 2022. Far and away the largest market for pharma investment is the USA, which now spendsalmost 60 cents
THE FUTURE OF BIOLOGICSSEE MORE ON THEPHARMALETTER.COM JAPAN PHARMA MARKET REVIEWMEXICO PHARMACEUTICAL MARKETPHARMACEUTICAL MARKET SIZEUS PHARMACEUTICAL MARKET Japan pharma market review. Gross domestic product (GDP) in Japan is about $5 trillion, and the country’s pharmaceutical market is one of the largest in the world, with figures from the Ministry of Health, Labour and Welfare (MHLW) indicating a market value of about $95 billion, including non-prescription medications. NOVO NORDISK TO EXPAND INSULIN CAPACITY IN RUSSIA 06-11-2020. Article Sanofi plans four-fold increase in insulin production in Russia. 31-10-2017. Article Novo Nordisk invests $60 million in expansion of Kalundborg site. 04-07-2016. Article Novo Nordisk plans to meet entire Russian demand for insulin over the next few years. 02-05-2016. AUTHORITATIVE PHARMA AND BIOTECH NEWS The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
GOVERNMENT AFFAIRS
BRIEF—India’s SII to extend freeze on exports of COVID-19 jabs. 19-05-2021. The world’s biggest vaccine maker, the Serum Institute of India (SII), plans to extend its halt on. Coronavirus Focus On Government Affairs India Infectious diseases Pharmaceutical Production Serum Institute of India Vaccines. InBrief.RARE DISEASES
Sarepta leaps on mainly positive SRP-5051 results in patients with DMD. 04-05-2021. Shares of Sarepta Therapeutics closed up nearly 9% at $77.11 yesterday, after the US rare diseases specialist. Biotechnology Drug Trial Duchenne Muscular dystrophy Musculoskeletal One to Watch Companies Rare diseases Research Sarepta Therapeutics SRP-5051 USA. BRIEF—CHINA BUYS 100 MILLION DOSES OF BIONTECH/PFIZER VACCINE BioNTech. BioNTech and Shanghai Fosun Pharmaceutical have agreed to supply China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against COVID-19. Approved in several countries including the UK, USA and Canada, the deal with China is subject to the product’s approval from the country’s medicinesregulator.
GENERICS NEWS
Viatris’ 2021 financial guidance misses expectations. Viatris, the newly-formed generics power-house resulting from the merger of Mylan and Pfizer’s Upjohn unit, saw its share fall more than 11% to $16.30 pre-market today, after it announced 2021 financial guidance. See allGenerics news.
BRIEF—ASTRAZENECA ANNOUNCES DEATH OF JOSÉ BASELGA, HEAD OF BRIEF—AstraZeneca announces death of José Baselga, head of oncology R&D. UK pharma major AstraZeneca yesterday announced the death of José Baselga, executive vice president oncology R&D, and member of its senior executive team. Pascal Soriot, chief executive of AstraZeneca, commented: “An outstanding scientific leader, Joséleaves a
IS PHARMA UNDERINVESTING IN MENTAL HEALTH? The global pharmaceutical industry has spent well over a trillion dollars on research and development in the last ten years, and analysts expect annual investment levels to grow by around 3% annually, reaching up to $200 billion per year by 2022. Far and away the largest market for pharma investment is the USA, which now spendsalmost 60 cents
THE FUTURE OF BIOLOGICSSEE MORE ON THEPHARMALETTER.COM JAPAN PHARMA MARKET REVIEWMEXICO PHARMACEUTICAL MARKETPHARMACEUTICAL MARKET SIZEUS PHARMACEUTICAL MARKET Japan pharma market review. Gross domestic product (GDP) in Japan is about $5 trillion, and the country’s pharmaceutical market is one of the largest in the world, with figures from the Ministry of Health, Labour and Welfare (MHLW) indicating a market value of about $95 billion, including non-prescription medications. NOVO NORDISK TO EXPAND INSULIN CAPACITY IN RUSSIA 06-11-2020. Article Sanofi plans four-fold increase in insulin production in Russia. 31-10-2017. Article Novo Nordisk invests $60 million in expansion of Kalundborg site. 04-07-2016. Article Novo Nordisk plans to meet entire Russian demand for insulin over the next few years. 02-05-2016.NEWS - ATC
6 hours ago · The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field. LOGIN - THE PHARMA LETTER The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
PHARMACEUTICAL NEWS
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
NEWS - AEF0117
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
MERGERS & ACQUISITIONS Roivant merging with Montes Archimedes to go public in $7.3 billion SPAC deal. 04-05-2021. Switzerland-based biopharma Roivant Sciences and Montes Archimedes Acquisition, a special purpose acquisition. Biotechnology Companies, mergers and acquisitions Management Montes Archimedes Acquisition Roivant Sciences Switzerland USA. BRIEF—CHINA BUYS 100 MILLION DOSES OF BIONTECH/PFIZER VACCINE BioNTech. BioNTech and Shanghai Fosun Pharmaceutical have agreed to supply China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against COVID-19. Approved in several countries including the UK, USA and Canada, the deal with China is subject to the product’s approval from the country’s medicinesregulator.
BRIEF—METYRAPONE EFFECTIVE AND SAFE IN ENDOGENOUS CUSHING HRA Pharma Rare Diseases, an affiliate of privately-held French healthcare company HRA Pharma, has revealed data from the six-month extension of PROMPT, the first ever prospective study designed to evaluate metyrapone long-term efficacy and tolerability inNEWS - KHK4083
Kyowa Kirin to get $400 million upfront in KHK4083 licensing deal. 02-06-2021. Shares of Japanese drugmaker Kyowa Kirin (TYO: 4151) were up 8% at 3,560 yen on news of a lucrative licensing. NEWS - MOSUNETUZUMAB The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
BRIEF—ICR ANNOUNCES APPOINTMENT OF NEW CEO BRIEF—ICR announces appointment of new CEO. Professor Kristian Helin, a world-leading cancer researcher with exceptional leadership experience in three different countries, will become chief executive of the UK’s Institute of Cancer Research, in September. Prof Helin is a pioneer in understanding how changes to the way the DNA code isread
This website uses cookies to improve your experience. Continue if youare OK with this.
Please read our privacy policyfor more
details.
_close_
* Login
* Subscribe
Search
Search
* Home
* M&A
* News
* News
* Pharmaceutical News * Biotechnology News* Generics News
* Biosimilars news
* In Brief
* Coronavirus
* Legal
* Patents and Trademarks* Asia Pacific
* World News
* In the Boardroom
* Companies
TOP NEWS STORIES
* AstraZeneca makes multi-million COVID-19 vaccine dose promise but efficacy doubts remainBiotechnology
* EC approval and activation of “Day One” access program forZolgensma in SMA
Biotechnology
* Insights
* Insights
* Analysis
* Special Report
* Interview
* Expert View
* From our correspondent * One to Watch Companies* Digital Pharma
* CEO Perspectives
TOP INSIGHTS STORIES * Russian government easing labeling requirements for producers oforphan drugs
Pharmaceutical
* Russian pharma market returning to normal post-COVID-19 spurtPharmaceutical
* Pricing, Policy, Regulation * Pricing, Policy, Regulation* FDA
* Pricing, reimbursement and access* EMA
* Regulation
* Government Affairs * Trump Administration* Brexit
TOP PRICINGSTORIES
* AstraZeneca makes multi-million COVID-19 vaccine dose promise but efficacy doubts remainBiotechnology
* EC approval and activation of “Day One” access program forZolgensma in SMA
Biotechnology
* Therapy Areas
* Therapy Areas
* Dermatologicals
* Oncology
* Neurological
* Rare diseases
* Hematology
* Cardio-vascular
* Diabetes
TOP THERAPY AREAS STORIES * EC approval and activation of “Day One” access program forZolgensma in SMA
Biotechnology
* Bayer's dominance in liver cancer challengedPharmaceutical
* Conference News
* Conference News
* ASCO 2020
* ESMO 2019
* AAIC 2019
* ADA 2019
* ATS 2019
* ESC Congress 2019
* ERS 2019
* ASH
TOP CONFERENCE NEWS STORIES * Erleada goes one better with OS data at ASCO 2020Pharmaceutical
* Opdivo plus Yervoy given concomitantly with chemo showed improvedsurvival in NSCLC
Biotechnology
* Events
* Reports
* Login
* Subscribe
THE PHARMA LETTER
Article
MODERNA SOARS ON LATEST POSITIVE MRNA CORONAVIRUS VACCINE DATA18-05-2020
*
RARE DISEASES:
Article
ILLUMINATING HEMOPHILIA*
FROM OUR CORRESPONDENT:Article
IS THE FDA KEEPING UP WITH DRUG APPROVALS AMIDST COVID-19?*
FEATURE:
Article
PHARMA MEETINGS GOING VIRTUAL IN 2020*
INTERVIEW:
Article
ROBUST DATA AND FLEXIBLE APPROACH PUT TEVA IN POLE POSITION WITH ANTI-CGRP DRUG IN UKArticle
EXPERT VIEW
GLOBAL PHARMA AND BIOTECH’S FIGHT AGAINST COVID-19: AN INVESTMENTPERSPECTIVE
Mark Brewer, who heads up the life sciences team at UK broker and M&A advisory company, finnCap, gives an overview of some of the growth companies that are currently actively working in the fight against coronavirus in an Expert View piece.LATEST IN BRIEF
* InBriefBRIEF—Trump warns of permanent stop to WHO funding unlessit makes changes
19-05-2020
* InBriefBRIEF—Independent pharmacies file suit against PBM15-05-2020
* InBriefBRIEF—Halozyme get $15 million milestone from Janssen15-05-2020
* InBriefBRIEF—China instigates bio-equivalence testing for genericinjectables
15-05-2020
LATEST PHARMACEUTICAL NEWS">
Article
BAYER'S DOMINANCE IN LIVER CANCER CHALLENGED19-05-2020
Paris-based Ipsen has announced data from a matching-adjusted indirect comparison (MAIC) of Cabometyx… * ArticleRussian government easing labeling requirements for producers of orphan drugs19-05-2020
* ArticleProtein degradation shows promise for Roche19-05-2020
* ArticleRussian pharma market returning to normal post-COVID-19spurt
19-05-2020
* ArticleITIF/WHO collaboration for innovation, urging open trade, in combating coronavirus19-05-2020
LATEST BIOTECHNOLOGY NEWS">
Article
ASTRAZENECA MAKES MULTI-MILLION COVID-19 VACCINE DOSE PROMISE BUT EFFICACY DOUBTS REMAIN19-05-2020
Anglo-Swedish drugmaker AstraZeneca and the UK government are putting plenty behind their efforts to… * ArticleEC approval and activation of “Day One” access program for Zolgensma in SMA19-05-2020
* ArticleTecentriq clocks up fifth US lung cancer approval19-05-2020
* ArticlePh III trial shows Mezzion Pharma's new orphan drug udenafil improved ventricular function19-05-2020
* ArticleInnovent bets on bringing checkpoint blocker to USA19-05-2020
LATEST GENERICS NEWS">
Article
RDIF AND CHEMRAR SEE POSITIVE INTERIM RESULTS FOR FAVIPIRAVIR INCORONAVIRUS THERAPY
14-05-2020
With strong momentum in Japanese research for novel coronavirus candidate favipiravir, Russian efforts… * ArticleRussian government to provide support to domestic producersof cheap drugs
12-05-2020
* ArticleApotex admits price fixing and accepts fine11-05-2020
* ArticleMylan mainly unscathed by pandemic disruption so far11-05-2020
* ArticleTeva soars as 1st-qtr beats expectations07-05-2020
LATEST BIOSIMILARS NEWS">
Article
TANYA ZHAROV VOWS TO HELP STRENGTHEN ALVOTECH AS LEADER IN BIOSIMILARS18-05-2020
Biosimilars specialist Alvogen has named Tanya Zharov its new deputy chief executive, based in Iceland. * ArticleProspects bright for Samsung Bioepis’ biosimilar toLucentis
18-05-2020
* ArticleBausch + Lomb licenses Stada and Xbrane’s Lucentisbiosimilar
06-05-2020
* ArticleFirst Rituxan biosimilar for RA launches in USA04-05-2020
* ArticleIndia’s Biocon gets EIR report for Bengaluru facilitiesfrom US FDA
16-04-2020
* Editor's Picks
* Most read
TOP 5 STORIES
1 of 5
*
MASSIVE WEIGHT LOSS OPPORTUNITY FOR NOVO NORDISK*
SORRENTO SOARS ON POSITIVE NEWS FROM COVID-19 ANTIBODY PROGRAM*
IS THE FDA KEEPING UP WITH DRUG APPROVALS AMIDST COVID-19?*
EXPERT WEIGHS UP DISTRIBUTION OPTIONS FOR COVID-19 VACCINE*
BOEHRINGER STRENGTHENS POSITION IN CANCER IMMUNOLOGY VIA ACQUISITIONTOP 5 STORIES
1 of 5
*
SORRENTO SOARS ON POSITIVE NEWS FROM COVID-19 ANTIBODY PROGRAM*
CANADA GETS HEAD START WITH COVID-19 VACCINE CANDIDATE*
LOOK BACK AT PHARMA NEWS IN THE WEEK TO MAY 15, 2020*
ENHERTU GAINS THIRD ‘BREAKTHROUGH’ STATUS, NOW FOR NSCLC*
J&J COLLABORATES WITH VIBALOGICS ON COVID-19 VACCINE DEVELOPMENTFDA BLOG
IS THE FDA KEEPING UP WITH DRUG APPROVALS AMIDST COVID-19?BOARDROOM
">
Article
TANYA ZHAROV VOWS TO HELP STRENGTHEN ALVOTECH AS LEADER IN BIOSIMILARS18-05-2020
Biosimilars specialist Alvogen has named Tanya Zharov its new deputy chief executive, based in Iceland. MERGERS & ACQUISITIONS MARCH 2020 PHARMACEUTICAL M&A ROUND-UP There has quietly been a significant series of pharma industry acquisitions during the month of March, even if much of the public focus on the sector is currently on its efforts fighting COVID-19.EVENTS
*
CPHI & P-MEC CHINA 2020 22-06-2020 - 24-06-2020Shanghai, China Since being introduced into China in 2001, CPhI China, starting with displaying API products, has been committed to showing the pharmaceutical strength of China to the world and helping Chinese pharmaceutical enterprises to go international.1
PrevNext
SIGN UP FOR OUR DAILY NEWSLETTER Our latest news direct to your inboxNewsletter
* Login
* Subscribe
LINKS
* About us
* Subscribe
* Contact us
* Terms and Conditions* Privacy Policy
* Drugs
* RSS
* PR Newswire Press Releases * Sponsorship/AdvertisingOUR MISSION
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in thefield.
CONTACT US
The Pharma Letter
39 to 43 Putney High StreetPutney
London
SW15 1SP
For trial and subscription enquiries please email subscriptions@thepharmaletter.com For editorial enquiries, press releases and events please email newsdesk@thepharmaletter.com For all other queries please email enquiries@thepharmaletter.com Agile web development by Byte9Back to top
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0